Comparative Pharmacology
Head-to-head clinical analysis: CARBIDOPA LEVODOPA AND ENTACAPONE versus RYTARY.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CARBIDOPA LEVODOPA AND ENTACAPONE versus RYTARY.
CARBIDOPA, LEVODOPA AND ENTACAPONE vs RYTARY
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Levodopa is a precursor to dopamine that crosses the blood-brain barrier and is converted to dopamine by aromatic L-amino acid decarboxylase, replenishing depleted dopamine in the striatum. Carbidopa inhibits peripheral decarboxylation of levodopa, increasing its availability to the brain and reducing peripheral side effects. Entacapone is a selective and reversible inhibitor of catechol-O-methyltransferase (COMT), primarily in the periphery, which prolongs the half-life and duration of action of levodopa by reducing its conversion to 3-O-methyldopa.
Levodopa is a dopamine precursor that crosses the blood-brain barrier and is converted to dopamine in the brain, thereby increasing dopamine levels in the substantia nigra and striatum. Carbidopa inhibits peripheral decarboxylation of levodopa, reducing peripheral side effects and increasing levodopa availability to the brain.
One tablet (carbidopa 25 mg/levodopa 100 mg/entacapone 200 mg) orally up to a maximum of 8 tablets per day in divided doses. Optimal dose individualized based on response and tolerance.
Initial: 23.75 mg/95 mg orally three times daily for 3 days, then increase to 36.25 mg/145 mg three times daily. Titrate based on response and tolerability. Maximum dose: 97.5 mg/390 mg three times daily.
None Documented
None Documented
Levodopa: 1-2 hours (short half-life necessitates frequent dosing with carbidopa to inhibit peripheral decarboxylation). Carbidopa: 2-3 hours. Entacapone: 1-2 hours (terminal half-life prolonged with levodopa). Clinical context: entacapone prolongs levodopa's half-life by inhibiting COMT.
Carbidopa: 2-3 hours; Levodopa: 1-2 hours (immediate-release component), levodopa elimination half-life extended to approximately 5-6 hours for the extended-release component; clinical context: allows once-daily dosing despite short half-life of IR component due to ER formulation
Levodopa: renal excretion of metabolites (dopamine, DOPAC, HVA) and unchanged drug (<1%); carbidopa: 70% renal as unchanged drug and metabolites; entacapone: 90% fecal (biliary), 10% renal.
Renal (approximately 80% as metabolites, including 3-O-methyldopa and other conjugates; <1% unchanged); biliary/fecal (approximately 10-15%)
Category A/B
Category C
Dopamine Precursor
Decarboxylase Inhibitor/Dopamine Precursor